Voyager Therapeutics, Inc. (VYGR)
| Market Cap | 143.78M |
| Revenue (ttm) | 132.24M |
| Net Income (ttm) | 17.92M |
| Shares Out | 37.58M |
| EPS (ttm) | 0.47 |
| PE Ratio | 8.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,614,120 |
| Open | 3.87 |
| Previous Close | 3.91 |
| Day's Range | 3.70 - 3.89 |
| 52-Week Range | 2.46 - 12.00 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | 7.07 (+86.5%) |
| Est. Earnings Date | Nov 8, 2021 |
About VYGR
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's dise...
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is 7.07, which is an increase of 86.54% from the latest price.
News
Voyager Posts Encouraging Preclinical Data For CNS-Directed Gene Therapy
Voyager Therapeutics Inc (NASDAQ: VYGR) has announced the presentation of preclinical data of GBA1 gene replacement therapy. The data demonstrated that a single intravenous (IV) dose of GBA1 gene replac...
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress...
Single AAV intravenous dose achieved widespread CNS distribution and sustained correction of GCase activity in multiple brain regions Single AAV intravenous dose achieved widespread CNS distribution and...
Top Biotech Penny Stocks to Watch With High Volume Right Now
Are these high volume biotech penny stocks worth adding to your watchlist right now? The post Top Biotech Penny Stocks to Watch With High Volume Right Now appeared first on Penny Stocks to Buy, Picks, N...
Implied Volatility Surging for Voyager (VYGR) Stock Options
Investors need to pay close attention to Voyager (VYGR) stock based on the movements in the options market lately.
VYGR Stock: The Huge Licensing Deal Sending Voyager Therapeutics Rocketing Higher
Here's the big licensing news that's sending shares of VYGR stock higher today as investors reassess this company's value moving forward. The post VYGR Stock: The Huge Licensing Deal Sending Voyager The...
Here's why Voyager Therapeutics is up 55%
Voyager Therapeutics Inc (NASDAQ: VYGR) announced that the group had inked a license option agreement that allows Pfizer Inc. (NYSE: PFE). As news of the deal became official and was doing the rounds, t...
Voyager Therapeutics Stock Soars On License Option Pact With Pfizer
Voyager Therapeutics Inc (NASDAQ: VYGR) has announced licensing option agreement with Pfizer Inc (NYSE: PFE) for capsids generated from Voyager's RNA-driven TRACER screening technology. Related: Voyag...
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enabl...
Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
Voyager Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, toda...
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -6.67% and -66.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorize...
Proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations
Analysts Estimate Voyager Therapeutics (VYGR) to Report a Decline in Earnings: What to Look Out for
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Voyager CEO Resigns After Company Turns Back To Discovery-Stage
Voyager Therapeutics, Inc (NASDAQ: VYGR) CEO and President Andre Turenne will step down as the beleaguered company announced it would move focus to early, discovery-stage efforts. The company's CMO and ...
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington's disease and maximizing opportunities created by TRACER TM gene therapy technology platform and next-generation targ...
Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders
Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at the Amer...
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Ant...
Findings to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy
Voyager Therapeutics' Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transd...
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurologica...
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 18.31% and 35.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington's disease in the fourth quarter of 2021
Earnings Preview: Voyager Therapeutics (VYGR) Q1 Earnings Expected to Decline
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength?
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...
Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy
Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new drug application for VY-HTT01, a gene therapy candidat...
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc....
Los Angeles, California--(Newsfile Corp. - March 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeuti...